+ Watch IMGN
on My Watchlist
The Company develops antibody-based anticancer therapeutics.
Great platform to generate money from other peoples success. The have learned how to monetize their tech, some interesting drugs in their own pipeline, looks pretty solid in the LONG LONG LONG run.
After the disappointment with Phase3-Marianne trial in 1st line HER2neu positive breast cancer and drug Kadcyla, IMGN just showed at ASCO with their new experimental drug for platinum-resistant ovarian cancer that the idea of pairing an antibody with a zytotoxic drug is working (proof of concept again). As they seem to have a lot of knowledge and patents in this, there might be more successful drugs in the future.Sooner or later one will come through, hopefully.Still long IMGN.
Wait for it to recover.
immunogen may have had it rough at the end of 2014 but still has many promising therapies for various types of cancers including NHL. Compared to big ticket biotech stocks, this one is a buy at 6.93 - - I see a 12 month target at 14.00 - I like the options too!
Dip provides a good entry point.
see a lot of value here, said Cramer. At current levels I'm a buyer
High valuations and low relative strength. Will probably continue to slide.
Big pipeline of potentially profitable new drugs.
I am hoping for a big year with clinical trials and partnered products.
1yr sales grwth 117% ,3yr sales grwth 33%
UBS must be trying to drive this down, don't fall for it...
With its AntiSense technology, this is a Biotech winner LT!
The technology is bearing fruit and could be applied to multiple cancers.
Immunogen's proprietary TAP technology is licensedto Genentech for their groundbreaking drug for HER2-positive metastatic breast cancer. This drug looks all set for approval within the very near future and its clinical trials data show significant increases in overall survival. This is a treatment that has the potential to transform the eway we treat breast cancer and has implications for other tumor types, too. When the drug is approved, the money will start to roll in for Immunogen.
Value at this price.
Undervalued comparing with SGEN
just watching it go down. Will buy around 8$
It only take 1 good drug
This is a great company based on a solid science foundation. It's platform is proving to work. Not only did TDM1 have phenomenal phase 2 results, but its partnerships with other companies are also doing very well. This indicates a lot more future value when these products get through development. I see this as a buy and anticipate the company will be acquired someday...hopefully by Roche.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions